Asgard’s CEO on the EUR 30 million Series A financing
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Erbjudande: Krypto visar motståndskraft – här kan du just nu handla kryptovalutor avgiftsfritt (annons)

Nyhet

Asgard’s CEO on the EUR 30 million Series A financing

Asgard’s CEO on the EUR 30 million Series A financing
Nyhet från Biostock
Publicerad: 22 Mar 2024 11:11

Asgard Therapeutics is a biotech based in Lund developing an immune “Trojan horse” to defeat cancer.

The company recently announced a € 30 million Series A financing to advance its cell reprogramming platform for immuno-oncology. Asgard’s CEO and co-founder Cristiana Pires stopped by the BioStock Studio to tell us all about it.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg
Läs hela artikeln hos Biostock

Nyhetsbrev